⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 12, 2024The LancetOpen Access

Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis

Huseyin Naci Peter J. Murphy Beth Woods James Lomas Jiang Wei Irene Papanicolas

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

The Commonwealth Fund.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Naci et al. (2024) studied this question.

synapsesocial.com/papers/69db24591e19c8ae08836b40 https://doi.org/10.1016/s0140-6736(24)02352-3

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020Cost-Effectiveness Analysis · 2022 · 6 citations
2IMPACT OF HEALTH TECHNOLOGY ASSESSMENTSother · 2002 · 14 citations
3Characteristics of cancer drug-indication pairs recommended for funding on the Australian Pharmaceutical Benefits Scheme (PBS), 2005-2025.Cohort Study · 2026
4Not playing with a full DEC: why development and evaluation committee methods for appraising new drugs may be inadequateeditorial · 1999 · 22 citations
5Inside the ‘Black Box’ of Pharmaceuticalisation: NICE, the Permissive Principle and the Case of Anticoagulantsother · 2026
6Measuring the impact of medicines regulatory interventions – Systematic review and methodological considerationsSystematic Review · 2017 · 90 citations
7Politicised Changes to the NICE Threshold Risk Making Cost-Effectiveness Analysis Performative, Not InformativeOriginal Research · 2026 · 2 citations
8Pharmacoeconomics and Health Economics in Drug Policy: A Systematic Review of Cost-Effectiveness and Budget Impact Analyses2025 · 2 citations
9Cangrelor versus crushed ticagrelor in acute myocardial infarction complicated by cardiogenic shock (DAPT-SHOCK-AMI): a randomised, double-blind trialThe Lancet · 2026
10Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trialThe Lancet · 2020

More from The Lancet

More from Brown University

More from University of York

More from London School of Economics and Political Science